ChromaDex Revenue and Competitors

Location

$81.7M

Total Funding

Health

Industry

Estimated Revenue & Valuation

  • ChromaDex's estimated annual revenue is currently $33.5M per year.(i)
  • ChromaDex received $5.0M in venture funding in October 2014.
  • ChromaDex's estimated revenue per employee is $274,426
  • ChromaDex's total funding is $81.7M.

Employee Data

  • ChromaDex has 122 Employees.(i)
  • ChromaDex grew their employee count by 11% last year.

ChromaDex's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Head DTC | VP, MarketplacesReveal Email/Phone
3
ControllerReveal Email/Phone
4
SVP Human ResourcesReveal Email/Phone
5
VP, FinanceReveal Email/Phone
6
VP QualityReveal Email/Phone
7
SVP, Global Scientific & Regulatory AffairsReveal Email/Phone
8
General Counsel & Corporate SecretaryReveal Email/Phone
9
SVP, Global Business Development & SalesReveal Email/Phone
10
VP R&DReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$9.3M71-7%N/AN/A
#2
$14.6M94-10%$71.2MN/A
Add Company

What Is ChromaDex?

ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®. For more, visit www.ChromaDex.com Like us on Facebook here: https://www.facebook.com/ChromaDex or follow us on Twitter @ChromaDex ChromaDex® is publicly-traded company (NASDAQ:CDXC).

keywords:N/A

$81.7M

Total Funding

122

Number of Employees

$33.5M

Revenue (est)

11%

Employee Growth %

N/A

Valuation

N/A

Accelerator

ChromaDex News

2022-04-19 - ChromaDex (NASDAQ:CDXC) Downgraded by Zacks ...

ChromaDex (NASDAQ:CDXC) Downgraded by Zacks Investment Research to Sell. Posted by admin on Apr 27th, 2022. Share on Twitter Share on Facebook Share on...

2022-04-17 - ChromaDex Appoints Ann Cohen and Kristin Patrick to its ...

LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ: CDXC) today announced that it has appointed two new members to its Board of...

2022-04-06 - ChromaDex External Research Program (CERP ...

LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC) today celebrates over 250 material transfer agreements (MTAs) through the...

2021-11-03 - ChromaDex Corporation Reports Third Quarter 2021 Financial Results - Form 8-K

ChromaDex Corporation Reports Third Quarter 2021 Financial Results Total company net sales of $17.3 million for the three months ended September 30, 2021, with Tru Niagen® net sales of $14.8 million, up 24% from the prior year quarter and gross margin of 61.1% for the quarter. LOS ANGELES, CA ...

2021-03-18 - ChromaDex to Present at the Zooming with LD Virtual Investor Conference

LOS ANGELES--(BUSINESS WIRE)--Mar 18, 2021-- ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting virtually at the Zooming with LD investor conference. The ChromaDex management team is scheduled t ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$12.2M12213%N/A
#2
$18.3M122N/AN/A
#3
$17.7M1226%N/A
#4
$17.7M122-14%N/A
#5
$17.7M12216%N/A

ChromaDex Funding

DateAmountRoundLead InvestorsReference
2013-10-22$UndisclosedUndisclosedDSM VenturingArticle
2014-10-01$5.0MUndisclosedHercules Technology Growth CapitalArticle